Highline Capital Management

Network Bio operates a clinical and molecular data library focused on facilitating precision medicine for common human diseases. Its platform serves as a centralized repository for clinical and molecular data, allowing researchers to analyze patterns and correlations. This analysis can lead to the development of new treatments and diagnostic tools, thereby advancing medical research and improving patient outcomes.

Proscia Inc. is a Philadelphia-based company that develops a cloud-based digital pathology platform aimed at enhancing cancer diagnosis and improving patient outcomes. Founded in 2014, Proscia's platform leverages advanced computing technologies to analyze data that is not perceptible to the human eye. By transforming this hidden data into actionable insights, the platform supports routine pathology operations and aids physicians in accelerating the development of life-saving medical advancements.

Proscia Inc. is a Philadelphia-based company that develops a cloud-based digital pathology platform aimed at enhancing cancer diagnosis and improving patient outcomes. Founded in 2014, Proscia's platform leverages advanced computing technologies to analyze data that is not perceptible to the human eye. By transforming this hidden data into actionable insights, the platform supports routine pathology operations and aids physicians in accelerating the development of life-saving medical advancements.

Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London, established in 2018. The company focuses on developing therapies for mental health disorders, utilizing psychedelic compounds and other innovative methods to address conditions such as depression, anxiety, and substance use disorders. ATAI collaborates with various partners and research institutions to advance its clinical-stage drug development pipeline, which includes multiple product candidates like psilocybin therapy, ketamine-based treatments, and other compounds aimed at enhancing mental well-being. The company's commitment to research in psychedelics and neuroscience drives its efforts to ensure the efficacy and safety of its therapies. Recognized for its contributions to mental health treatment, ATAI has secured partnerships and funding to support its initiatives, gaining attention for its advancements in understanding and treating mental health disorders.

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for neurological diseases. The company's proprietary pipeline includes several product candidates, notably LP352, a next-generation 5-HT2C agonist intended for treating developmental and epileptic encephalopathies. Additionally, Longboard is evaluating LP143, a full agonist of the cannabinoid type 2 receptor, which targets conditions such as amyotrophic lateral sclerosis and Parkinson's disease, as well as LP659, a selective modulator for multiple central nervous system neuroinflammatory disorders. Longboard Pharmaceuticals aims to optimize pharmacology and pharmacokinetics across its drug candidates, enhancing therapeutic outcomes for patients with rare neurological conditions. The company was incorporated in 2020 and was previously known as Arena Neuroscience, Inc.

Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.